Vertex cystic fibrosis combination succeeds in late-stage trials

(Reuters) - Vertex Pharmaceuticals Inc said on Tuesday its Kalydeco cystic fibrosis treatment given with an experimental drug demonstrated significant improvements in lung function in a pair of late-stage trials the company plans to use to seek approval of the combination therapy.

Source: Reuters: Health - March 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news